Conclusion:
This study revealed worse outcomes in pregnant patients infected with
COVID-19 and with associated transaminitis. Due to limited data and
overall information on COVID-19, it is difficult to determine if
transaminitis serves as a predictor of worse outcomes, or if it is
solely a marker of worsening disease. As more data becomes available on
pregnant patients with COVID-19, it will be important to assess the
effect of transaminitis on maternal and neonatal outcomes and if it is
consistently predictive of poor outcomes. In the future, it will be
crucial to determine if transaminitis can help determine clinical
guidelines, such as timing of delivery.
Disclosure of Interest: All authors report no conflicts of
interest.
Contribution to authorship : JAY, SJW, and GR conceived and
designed the study. GR and SK supervised the study. SF was responsible
for literature review. JAY, SJW and SF acquired and analyzed the data.
JAY did the statistical analysis. JAY, SJW, SF, SK, and GR interpreted
the data, were involved in preparing the manuscript and contributed to
the critical revision of the manuscript. The corresponding author
attests that all listed authors meeting authorship criteria. All authors
accept responsibility for the paper as published.
Details of ethic approval : This study was approved by New York
Medical College and Westchester Medical College Institutional Review
Board (IRB), protocol #14296 on September 8th, 2020.
Written consent was not required for this study because it was a case
series and retrospective in nature. Therefore, the research involves no
risk to the subjects the waiver or alteration will not adversely affect
the rights and welfare of the subjects; the research could not
practicably be carried out without the waiver or alteration (i.e., it is
impracticable to get consent of the subjects).
Funding: No sources of funding or financial support provided
for this research.
Acknowledgements: None.